Score Breakdown
Trash.
Sarepta is a deteriorating franchise facing a perfect storm: ELEVIDYS's addressable market has been permanently shrunk by the black box warning and non-ambulatory restriction, the PMO franchise faces a 2027 patent cliff with next-gen competitors (Dyne, Solid Bio) already in late-stage trials, and the company is burning $200M+ per quarter in cash with only ~$750M in liquidity. The reported Q1 2026 profitability is an accounting mirage driven by $325M in non-cash Roche deferred revenue recognition. At 25% annual dilution, equity holders are being massively diluted. The siRNA pipeline offers long-term optionality but is years from commercialization and faces its own competitive risks. With active patent litigation (Regenx reversal), securities class-action suits, negative European reimbursement decisions, and a CEO transition underway, the risk/reward is strongly skewed to the downside. The 27.6% short interest reflects legitimate fundamental concerns rather than just technical positioning.
Overvalued.
Major red flags in SEC filings.
Shares melting fast.
Neutral.
Cash flow positive.
Heavy bearish bets.
Below average.
🐻 Why Bears Hate It
The core bear case centers on the 'narrowing moat' and safety-capped revenue. With Elevidys now blocked for non-ambulatory patients—the most severe segment of the DMD population—the addressable market has shrunk by roughly 30-40%. Furthermore, the company faces a massive 'patent cliff' starting in 2027 for its core PMO franchise (Exondys 51, Vyondys 53). Skeptics point to the 2026 revenue guidance as evidence that the gene therapy launch has plateaued due to safety concerns and lack of reimbursement in key European markets like Germany and France (Sources: Porter's Five Forces, Ambiom).
🔍 What's In The SEC Filings
SRPT is currently a litigation-heavy cash burner whose reported profitability is an accounting mirage driven by one-time deferred revenue recognition.
Artificial Net Income via Partner Rejection
“In February 2026, Roche declined to exercise an Option for certain program rights, which resulted in the immediate recognition of $325.0 million of collaboration revenue during the three months ended March 31, 2026.”
The company reported $331M in net income, but $325M of this was non-cash deferred revenue recognized specifically because a partner (Roche) chose NOT to continue a program. Without this one-time accounting catch-up, the company would have been near break-even despite massive product revenue declines.
Aggressive Cash Burn vs Liquidity
“Net cash used in operating activities [-202,683] ... As of March 31, 2026, the Company had $748.3 million of cash, cash equivalents, restricted cash and investments.”
The company burned $202.7M in operating cash in Q1 2026 alone. With only $748.3M in total liquidity, they have less than four quarters of runway at the current burn rate before needing a significant capital raise or debt restructuring.
Federal Circuit Patent Reversal
“Plaintiffs appealed to the U.S. Court of Appeals for the Federal Circuit (the “Federal Circuit”), which reversed the district court's decision on February 20, 2026, and remanded the case for further proceedings.”
A previously favorable summary judgment in the Regenx/U-Penn patent infringement lawsuit (which seeks royalties and treble damages on ELEVIDYS) was overturned. This re-opens the company to massive liability on its primary gene therapy product.
Securities Class Action and Derivative Suits
“The complaint alleges violations of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 in connection with disclosures made regarding ELEVIDYS’s safety and efficacy.”
Multiple lawsuits (Securities Action and Derivative Actions) allege management misled shareholders regarding the safety profile of ELEVIDYS, which eventually required a boxed warning and a temporary shipment hold.
Negative Gross Margins on Roche Supply
“During the three months ended March 31, 2026, Roche product cost of sales exceeded Roche contract manufacturing revenue as a portion of scrapped and expired materials as well as the write-offs of certain batches of ELEVIDYS that did not meet quality specifications.”
Manufacturing yields are problematic; the company is losing money on its supply agreement with Roche ($39.6M cost vs $31.1M revenue) due to quality failures and batch write-offs.
The intrinsic value should be heavily discounted to account for the $12.1 billion in potential milestone obligations and the probability of significant settlement costs or royalty overrides from the Genzyme and Regenx litigations. Current PE ratios are useless given the non-cash nature of the Q1 profit.
ELEVIDYS product revenue fell from $375M (Q1 2025) to $102M (Q1 2026), a 72% drop, following safety events and label restrictions that removed the non-ambulatory population from the indication.